Published Online
on June 16, 2008

A more recent version of this article appeared on July 1, 2008

This Article Full Text (PDF) All Versions of this Article: 118/1/49    most recent CIRCULATIONAHA.107.747642v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thiele, H. Articles by Schuler, G. Search for Related Content PubMed PubMed Citation Articles by Thiele, H. Articles by Schuler, G. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Angioplasty Heart Attack Related Collections Platelet function inhibitors Catheter-based coronary interventions: stents Acute coronary syndromes CT and MRI Acute myocardial infarction Related Article

Submitted on October 22, 2007
Accepted on May 2, 2008

Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarction Trial

Holger Thiele MD^*, Kathrin Schindler MD, Josef Friedenberger MD, Ingo Eitel MD, Georg Fürnau MD, Eigk Grebe MD, Sandra Erbs MD, Axel Linke MD, Sven Möbius-Winkler MD, Dietmar Kivelitz MD, and Gerhard Schuler MD

From the University of Leipzig, Heart Center, Department of Internal Medicine, Cardiology (H.T., J.F., I.E., G.F., E.G., S.E., A.L., S.M.-W., G.S.), and Department of Radiology (K.S., D.K.), Leipzig, and Charité, Universitätsmedizin Berlin, Department of Radiology, Berlin (D.K.), Germany.

^* To whom correspondence should be addressed. E-mail: thielh{at}medizin.uni-leipzig.de.

Background—Abciximab reduces major adverse cardiac events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI). Intracoronary abciximab bolus application results in high local drug concentrations and may be more effective than a standard intravenous bolus.

Methods and Results—Patients undergoing primary PCI were randomized to either intracoronary (n=77) or intravenous (n=77) bolus abciximab administration with subsequent 12-hour intravenous infusion. The primary end point was infarct size and extent of microvascular obstruction as assessed by delayed enhancement magnetic resonance. Secondary end points were ST-segment resolution at 90 minutes, Thrombolysis in Myocardial Infarction flow and perfusion grades after PCI, and the occurrence of major adverse cardiac events within 30 days. The median infarct size was 15.1% (interquartile range, 6.1% to 25.2%) in the intracoronary versus 23.4% (interquartile range, 13.6% to 33.2%) in the intravenous group (P=0.01). Similarly, the extent of microvascular obstruction was significantly smaller in intracoronary compared with intravenous abciximab patients (P=0.01). Myocardial perfusion measured as early ST-segment resolution was significantly improved in intracoronary patients with an absolute ST-segment resolution of 77.8% (interquartile range, 66.7% to 100.0%) versus 70.0% (interquartile range, 45.2% to 83.5%; P=0.006). The Thrombolysis in Myocardial Infarction flow after PCI was not different between treatment groups (P=0.51), but there was a trend toward an improved perfusion grade (P=0.09). There also was a trend toward a lower major adverse cardiac event rate after intracoronary versus intravenous abciximab application (5.2% versus 15.6%; P=0.06; relative risk, 0.33; 95% CI, 0.09 to 1.05).

Conclusions—Intracoronary bolus administration of abciximab in primary PCI is superior to standard intravenous treatment with respect to infarct size, extent of microvascular obstruction, and perfusion.

Key words: angioplasty • infarction • magnetic resonance imaging • platelets • reperfusion

Related Article:

Clinical Summaries
Circulation 2008 118: 1-2. [Extract] [Full Text]

This article has been cited by other articles:

				G. Niccoli, F. Burzotta, L. Galiuto, and F. Crea Myocardial no-reflow in humans. J. Am. Coll. Cardiol., July 21, 2009; 54(4): 281 - 292. [Abstract] [Full Text] [PDF]

				A. Witkowski, P. Maciejewski, W. Wasek, L. A. Malek, M. Niewada, B. Kaminski, J. Drzewiecki, M. Kosmider, J. Kubica, W. Ruzyllo, et al. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality Eur. Heart J., July 2, 2009; 30(14): 1736 - 1743. [Abstract] [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF]

				M. Abdellaoui, G. Rioufol, and G. Finet Letter by Abdellaoui et al Regarding Article, "Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention" Circulation, January 27, 2009; 119(3): e19 - e19. [Full Text] [PDF]

				H. Thiele, J. Friedenberger, I. Eitel, G. Furnau, E. Grebe, S. Erbs, A. Linke, S. Mobius-Winkler, G. Schuler, K. Schindler, et al. Response to Letter Regarding Article, "Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention" Circulation, January 27, 2009; 119(3): e20 - e20. [Full Text] [PDF]

				G. De Luca Adjunctive antithrombotic therapy during primary percutaneous coronary intervention Eur. Heart J. Suppl., December 1, 2008; 10(suppl_J): J2 - J14. [Abstract] [Full Text] [PDF]

				B. S. Coller and S. J. Shattil The GPIIb/IIIa (integrin {alpha}IIb{beta}3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend Blood, October 15, 2008; 112(8): 3011 - 3025. [Abstract] [Full Text] [PDF]

				Intracoronary Versus Intravenous Abciximab Delivery Journal Watch Cardiology, July 30, 2008; 2008(730): 3 - 3. [Full Text]

				C. M. Gibson, C. Zorkun, and V. Kunadian Intracoronary Administration of Abciximab in ST-Elevation Myocardial Infarction Circulation, July 1, 2008; 118(1): 6 - 8. [Full Text] [PDF]